North of $20. Results expected by early Q2.
See today's action in FURX after reporting top line results.
We will see share price north of $20 after ITMN has announced positive trial results.
Sentiment: Strong Buy
says Summer Street
After STML has defined the schedule this stock will take off.
Poor research - STML has $80m on hand which should get them well into 2016. No capital raise expected near term
With a billion dollar drug in phase III RGDO is facing its first catalyst in April. The company is looking for safety data for REG1 the lead product candidate which shall replace Heparin and Angiomax for use in preventing clotting. Stay tuned!!!